EPJ Web Conf.
Volume 255, 2021EOS Annual Meeting (EOSAM 2021)
|Number of page(s)||4|
|Section||Early Stage Researcher Session|
|Published online||18 November 2021|
Intracellular SERS monitoring of drug release from plasmonic-assisted biosilica nanoparticles
1 Institute of Applied Science and Intelligent Systems (ISASI), National Research Council of Naples, Via Pietro Castellino 111, Italy.
2 Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131, Italy
3 Institute of Biochemistry and Cell Biology (IBBC), National Research Council of Naples, Via Pietro Castellino 111, Italy
4 Institute of Genetics and Biophysics (IGB), National Research Council of Naples, Via Pietro Castellino 111, Italy
* Corresponding author: email@example.com
Published online: 18 November 2021
Nanoscale delivery systems have been investigated for therapy due to their advantages, including the sustained delivery of drugs to cells and reduction of systemic toxicity compared to conventional treatments. However, their application is still hampered by experimental challenges, such as the investigation of the drug release in cells rather than in vitro. Here, we describe a hybrid nanoplatform for monitoring the drug release in living colorectal cancer (CRC) cells by Surface-Enhanced Raman Scattering (SERS). Specifically, the anticancer drug Galunisertib is encapsulated in diatomite nanoparticles (DNPs) decorated by gold nanoparticles (AuNPs) and capped by gelatin. The combination of DNP loading capacities with the Raman enhancement of Galunisertib provided by AuNPs enables bio-imaging and drug delivery without using fluorophores or markers, avoiding fluorescence-quenching issues. Thanks to the Raman enhancement of Galunisertib, the drug release profile is monitored and quantified in living cells by SERS with a femtogram scale resolution. When the gelatin shell is digested by proteases, Galunisertib is released and its SERS spectrum decreases, allowing real-time quantification in CRC cells. The therapeutic efficiency of the Galunisertib delivery platform offers an alternative route for lowering drug dose and toxicity.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.